Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1 8 Jan, 2020 | 08:37h | UTC Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study – Clinical Infectious Diseases (free PDF)